Table E5.
Absolute risk for switching to an angiotensin-II receptor blocker after treatment with angiotensin converting enzyme inhibitors in the general population, stratified by age, sex, and body mass index (BMI)
| Characteristic | General population |
|||
|---|---|---|---|---|
| Men |
Women |
|||
| Rate/1000 | NNT overall | Rate/1000 | NNT overall | |
| BMI <20 | ||||
| Age <40 y | 41 | 24 | 74 | 14 |
| Age 40-49 y | 57 | 18 | 140 | 7 |
| Age 50-59 y | 69 | 14 | 112 | 9 |
| Age >60 y | 68 | 15 | 114 | 9 |
| BMI 20-24 | 0 | 0 | ||
| Age <40 y | 63 | 16 | 99 | 10 |
| Age 40-49 y | 81 | 12 | 133 | 8 |
| Age 50-59 y | 101 | 10 | 165 | 6 |
| Age >60 y | 114 | 9 | 176 | 6 |
| BMI ≥25 | 0 | 0 | ||
| Age <40 y | 82 | 12 | 101 | 10 |
| Age 40-49 y | 107 | 9 | 157 | 6 |
| Age 50-59 y | 129 | 8 | 184 | 5 |
| Age >60 y | 135 | 7 | 192 | 5 |
NNT, number needed to treat with an angiotensin converting enzyme inhibitor for one person to switch to an angiotensin-II receptor blocker.